The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Protein Kinase Inhibitors: Insights into Drug Design from Structure
Open accessAbstract
Protein kinases are targets for treatment of a number of diseases. This review focuses on kinase inhibitors that are in the clinic or in clinical trials and for which structural information is available. Structures have informed drug design and have illuminated the mechanism of inhibition. We review progress with the receptor tyrosine kinases (growth factor receptors EGFR, VEGFR, and FGFR) and nonreceptor tyrosine kinases (Bcr-Abl), where advances have been made with cancer therapeutic agents such as Herceptin and Gleevec. Among the serine-threonine kinases, p38, Rho-kinase, cyclin-dependent kinases, and Chk1 have been targeted with productive results for inflammation and cancer. Structures have provided insights into targeting the inactive or active form of the kinase, for targeting the global constellation of residues at the ATP site or less conserved additional pockets or single residues, and into targeting noncatalytic domains.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Mitogen-Activated Protein (MAP) Kinase Pathways: Regulation and Physiological Functions*
Pearson, G., Robinson, F., Beers Gibson, T., Xu, B.-E., Karandikar, M., Berman, K., & Cobb, M. H. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.2.0428 · Cited by 4,034
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Protein kinases — the major drug targets of the twenty-first century?
Cohen, P. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd773 · Cited by 2,186
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Research works printed but not linked: 9
- D. J. Pratt J. A. Endicott M. E. Noble Curr. Opin. Drug Discov. Dev. in press.
- J. Baselga, L. A. Hammond, Oncology63, (Suppl. 1), 6 (2002).
- F. J. Giles, Oncology (Huntington)16, 23 (2002).
- 10.1007/s11864-001-0070-0 · doi:10.1007/s11864-001-0070-0
- 10.1345/aph.1A162 · doi:10.1345/aph.1a162 · Paper page
- G. Shapiroet al., Proc. Am. Soc. Clin. Oncol.22, 199 (2003).
- 10.1021/ar0201198 · doi:10.1021/ar0201198
- B. Nagaret al., Cancer Res.62, 4236 (2002).
- 10.1016/j.str.2003.09.020 · DOI
Cited by
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
G1 cell-cycle control and cancer
Massagué, J. (2004) · Nature · doi:10.1038/nature03094 · Cited by 1,224
GraphDTA: predicting drug–target binding affinity with graph neural networks
Nguyen, T., Le, H., Quinn, T. P., Nguyen, T., Le, T. D., & Venkatesh, S. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa921 · Cited by 1,220
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Multidimensional Drug Profiling By Automated Microscopy
Perlman, Z. E., Slack, M. D., Feng, Y., Mitchison, T. J., Wu, L. F., & Altschuler, S. J. (2004) · Science · doi:10.1126/science.1100709 · Cited by 660
Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678
“Activating mutations of protein kinases contribute to the development of human cancers (1) and have led to the development of kinase inhibitors that target these oncogenic forms (2).”
BackgroundFeatures of Selective Kinase Inhibitors
Knight, Z. A., & Shokat, K. M. (2005) · Chemistry & Biology · doi:10.1016/j.chembiol.2005.04.011 · Cited by 657
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
Pharmacological inhibitors of glycogen synthase kinase 3
MEIJER, L., FLAJOLET, M., & GREENGARD, P. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.006 · Cited by 584
Binding of Small-Molecule Ligands to Proteins: “What You See” Is Not Always “What You Get”
Mobley, D. L., & Dill, K. A. (2009) · Structure · doi:10.1016/j.str.2009.02.010 · Cited by 584
How Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560
Halogen Bonding—A Novel Interaction for Rational Drug Design?
Lu, Y., Shi, T., Wang, Y., Yang, H., Yan, X., Luo, X., Jiang, H., & Zhu, W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9000133 · Cited by 559
Experimental Binding Energies in Supramolecular Complexes
Biedermann, F., & Schneider, H.-J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00583 · Cited by 554
Mycobacterium tuberculosis and the Macrophage: Maintaining a Balance
Pieters, J. (2008) · Cell Host & Microbe · doi:10.1016/j.chom.2008.05.006 · Cited by 503
Van Roey, K., Uyar, B., Weatheritt, R. J., Dinkel, H., Seiler, M., Budd, A., Gibson, T. J., & Davey, N. E. (2014) · Chemical Reviews · doi:10.1021/cr400585q · Cited by 502
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
Wu, P., Nielsen, T. E., & Clausen, M. H. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.008 · Cited by 457
The Epidermal Growth Factor Receptor System in Skin Repair and Inflammation
Pastore, S., Mascia, F., Mariani, V., & Girolomoni, G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701184 · Cited by 443
Zhao, Z., Wu, H., Wang, L., Liu, Y., Knapp, S., Liu, Q., & Gray, N. S. (2014) · ACS Chemical Biology · doi:10.1021/cb500129t · Cited by 433
Targeting Plasmodium PI(4)K to eliminate malaria
McNamara, C. W., Lee, M. C. S., Lim, C. S., Lim, S. H., Roland, J., Nagle, A., Simon, O., Yeung, B. K. S., Chatterjee, A. K., McCormack, S. L., et al. (2013) · Nature · doi:10.1038/nature12782 · Cited by 431
The Structural Basis for Control of Eukaryotic Protein Kinases
Endicott, J. A., Noble, M. E. M., & Johnson, L. N. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052410-090317 · Cited by 427
Self-citationInhibitors of Protein Tyrosine Phosphatases: Next‐Generation Drugs?
Bialy, L., & Waldmann, H. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461517 · Cited by 420
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 411
Indolocarbazole natural products: occurrence, biosynthesis, and biological activity
Sánchez, C., Méndez, C., & Salas, J. A. (2006) · Nat. Prod. Rep. · doi:10.1039/b601930g · Cited by 407
New approaches to molecular cancer therapeutics
Collins, I., & Workman, P. (2006) · Nature Chemical Biology · doi:10.1038/nchembio840 · Cited by 391
Rational Approaches to Improving Selectivity in Drug Design
Huggins, D. J., Sherman, W., & Tidor, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2010332 · Cited by 367
Identification of chemically diverse Chk1 inhibitors by receptor-based virtual screening
Foloppe, N., Fisher, L. M., Howes, R., Potter, A., Robertson, A. G. S., & Surgenor, A. E. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.03.021 · Cited by 363
Roscovitine Targets, Protein Kinases and Pyridoxal Kinase
Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500806200 · Cited by 356
In Situ Kinase Profiling Reveals Functionally Relevant Properties of Native Kinases
Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E., Herring, C., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.011 · Cited by 348
Activation pathway of Src kinase reveals intermediate states as targets for drug design
Shukla, D., Meng, Y., Roux, B., & Pande, V. S. (2014) · Nature Communications · doi:10.1038/ncomms4397 · Cited by 333
Torreele, E., Bourdin Trunz, B., Tweats, D., Kaiser, M., Brun, R., Mazué, G., Bray, M. A., & Pécoul, B. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000923 · Cited by 325
Molecular genetics of multiple endocrine neoplasia types 1 and 2
Marx, S. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1610 · Cited by 322
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Targeting innate immunity protein kinase signalling in inflammation
Gaestel, M., Kotlyarov, A., & Kracht, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2829 · Cited by 316
Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.004 · Cited by 310
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
Knowles, P. P., Murray-Rust, J., Kjær, S., Scott, R. P., Hanrahan, S., Santoro, M., Ibáñez, C. F., & McDonald, N. Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605604200 · Cited by 302
Structure and function of Polo-like kinases
Lowery, D. M., Lim, D., & Yaffe, M. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208280 · Cited by 293
Structural Basis of Constitutive Activity and a Unique Nucleotide Binding Mode of Human Pim-1 Kinase
Qian, K. C., Wang, L., Hickey, E. R., Studts, J., Barringer, K., Peng, C., Kronkaitis, A., Li, J., White, A., Mische, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409123200 · Cited by 292
Phosphate Recognition in Structural Biology
Hirsch, A. K. H., Fischer, F. R., & Diederich, F. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200603420 · Cited by 287
Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium
Konkankit, C. C., Marker, S. C., Knopf, K. M., & Wilson, J. J. (2018) · Dalton Transactions · doi:10.1039/c8dt01858h · Cited by 284
Young, M. A., Shah, N. P., Chao, L. H., Seeliger, M., Milanov, Z. V., Biggs, W. H., Treiber, D. K., Patel, H. K., Zarrinkar, P. P., Lockhart, D. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2788 · Cited by 276
Pharmacogenetics and drug development: the path to safer and more effective drugs
Roses, A. D. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1432 · Cited by 268
A conserved protonation-dependent switch controls drug binding in the Abl kinase
Shan, Y., Seeliger, M. A., Eastwood, M. P., Frank, F., Xu, H., Jensen, M. Ø., Dror, R. O., Kuriyan, J., & Shaw, D. E. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811223106 · Cited by 262
Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
Green, T. P., Fennell, M., Whittaker, R., Curwen, J., Jacobs, V., Allen, J., Logie, A., Hargreaves, J., Hickinson, D. M., Wilkinson, R. W., et al. (2009) · Molecular Oncology · doi:10.1016/j.molonc.2009.01.002 · Cited by 238
Sensing Phosphatase Activity by Using Gold Nanoparticles
Choi, Y., Ho, N., & Tung, C. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200603735 · Cited by 259
Protein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 256
Self-citationEngineering Nanocomposite Materials for Cancer Therapy
Minelli, C., Lowe, S. B., & Stevens, M. M. (2010) · Small · doi:10.1002/smll.201000523 · Cited by 255
Smith, A. J. T., Zhang, X., Leach, A. G., & Houk, K. N. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm800498e · Cited by 193
Development of specific Rho-kinase inhibitors and their clinical application
Tamura, M., Nakao, H., Yoshizaki, H., Shiratsuchi, M., Shigyo, H., Yamada, H., Ozawa, T., Totsuka, J., & Hidaka, H. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.06.015 · Cited by 178
NMR Characterization of Kinase p38 Dynamics in Free and Ligand‐Bound Forms
Vogtherr, M., Saxena, K., Hoelder, S., Grimme, S., Betz, M., Schieborr, U., Pescatore, B., Robin, M., Delarbre, L., Langer, T., et al. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502770 · Cited by 145
Luzon-Toro, B., de la Torre, E. R., Delgado, A., Perez-Tur, J., & Hilfiker, S. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm151 · Cited by 122
Targeting tumour microenvironment by tyrosine kinase inhibitor
Tan, H.-Y., Wang, N., Lam, W., Guo, W., Feng, Y., & Cheng, Y.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0800-6 · Cited by 107
Saito, H., Hirano, H., Nakagawa, H., Fukami, T., Oosumi, K., Murakami, K., Kimura, H., Kouchi, T., Konomi, M., Tao, E., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.099036 · Cited by 92
COLOGNATO, R., LAURENZA, I., FONTANA, I., COPPEDE, F., SICILIANO, G., COECKE, S., ARUOMA, O., BENZI, L., & MIGLIORE, L. (2006) · Clinical Nutrition · doi:10.1016/j.clnu.2005.10.005 · Cited by 81
Modeling of metal interaction geometries for protein–ligand docking
Seebeck, B., Reulecke, I., Kämper, A., & Rarey, M. (2008) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21818 · Cited by 67
Ishikawa, T., Takahashi, K., Ikeda, N., Kajimoto, Y., Hagiya, Y., Ogura, S.-I., Miyatake, S.-I., & Kuroiwa, T. (2011) · Pharmaceutics · doi:10.3390/pharmaceutics3030615 · Cited by 34
An, R., Hagiya, Y., Tamura, A., Li, S., Saito, H., Tokushima, D., & Ishikawa, T. (2009) · Pharmaceutical Research · doi:10.1007/s11095-008-9738-5 · Cited by 34
PKD autoinhibition in trans regulates activation loop autophosphorylation in cis
Reinhardt, R., Hirzel, K., Link, G., Eisler, S. A., Hägele, T., Parson, M. A. H., Burke, J. E., Hausser, A., & Leonard, T. A. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2212909120 · Cited by 13
Saito, H., An, R., Hirano, H., & Ishikawa, T. (2010) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.25.72 · Cited by 7
Differential Response and Resistance to KRAS-Targeted Therapy
Liu, Z., Lenz, H., Yu, J., & Zhang, L. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.23908 · Cited by 7
Metadata
- Authors
- Noble, M. E. M., Endicott, J. A., & Johnson, L. N.
- Venue
- Science
- Published
- 2004-03-19
- Volume
- 303
- Issue
- 5665
- Pages
- 1800-1805
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2138072853
- Cited by
- 1,198
- References
- 67
- FWCI
- 30.40
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.